Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 19/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283833 | 0.95 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2284068 | 0.94 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2284382 | 0.92 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL12375770 | 0.91 | ADORA3 (0.88) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13746388 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1389191 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4759873 | 0.91 | ADORA3 (0.85) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1389184 | 0.90 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL2283773 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4758021 | 0.89 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | claimed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | claimed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | MCNC ENTERPRISE FUND, L.P. | 2011-08-04 | — | — | US | claimed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | claimed |
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | claimed |
| EP-1499614-A1 | ADENOSINE A3 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003095457-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | claimed |
| US-6448253-B1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-09-10 | — | — | US | claimed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558323-B2 | Particle formation and morphology | ELEKTROFI, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | ELEKTROFI INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ELEKTROFI INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6448253-B1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6407236-B1 | TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS | MEDCO RESEARCH, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6326390-B1 | ADMINISTERING ADENOSINE A1 | KING PHARMACEUTICALS RESEACH AND DEVELOPMENT, INC. | 2001-12-04 | — | — | US | disclosed |
| WO-2000010391-A1 | THE USE OF ADENOSINE A3 RECEPTOR ANTAGONISTS TO INHIBIT TUMOR GROWTH | MEDCO RESEARCH, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ALB, TNF, TTR | ADORA3 4580/4885ADORA2A 3439/4885ADORA1 4507/4885 |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | CD38, PARP1, PARP11 | ADORA3 23/4885ADORA2A 16/4885ADORA1 25/4885 |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | ADORA3 1969/4885ADORA2A 2833/4885ADORA1 2871/4885 |
| US-20110190324-A1 | METHODS OF TREATING ATHEROSCLEROSIS | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-12558323-B2 | Particle formation and morphology | CD63, EXOSC10, EPCAM | ADORA3 3873/4885ADORA2A 3001/4885ADORA1 3176/4885 |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | FLNB, FLNA, FUS | ADORA3 3107/4885ADORA2A 3104/4885ADORA1 2292/4885 |
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.